SMARCA2 and small cell lung carcinoma: 49,50 Our in vivo assessments with the orallybioavailable SMARCA2/4 PROTAC degrader, AU-24118, demonstrated a favorabletolerability profile alongside significant anti-tumor efficacy in multiple SCLC-Pand MM preclinical models.